NDAINJECTIONINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORLOPAM (fenoldopam mesylate) is an intravenous dopamine-1 receptor agonist approved in 1997 for the management of severe hypertension. It works by selectively stimulating dopamine-1 receptors, leading to vasodilation and reduced peripheral vascular resistance. The drug is administered as an injectable solution in acute care settings.
LOE Approaching
As an approaching LOE product with moderate competitive pressure (30), the brand team is likely focused on maintaining market share and managing transition planning rather than aggressive expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CORLOPAM offers limited career growth due to zero linked job postings and approaching LOE status. Roles focus on maintaining existing hospital relationships and managing competitive erosion rather than building new markets or launching innovations.
Brand ManagerField Sales Representative
Worked on CORLOPAM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.